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Background: During human (HIV) and simian (SIV) immunodeficiency virus infection, loss of CD4+ T cells and
progression to AIDS are associated with a decline in antibody titers to the viral Gag protein, while antibodies to the
Env protein remain high, suggesting a T cell independent antibody response to Env.
Results: To explore differential regulation of Gag and Env antibody responses, immunocompetent BALB/c and T
cell deficient nude mice were immunized with virus like particles (VLP) of simian immunodeficiency virus or
adenoviral vectors expressing SIV Gag and Env. High levels of antibodies against Gag and Env could only be
induced in immunocompetent mice, but not in the immunodeficient mice. Thus, neither cells expressing Env after
adenoviral gene transfer nor VLPs induce a T cell independent primary anti-Env antibody response. However,
secondary B cell responses to Env, but not to Gag, were observed in immunodeficient mice after transfer of primed
B cells and boosting with VLPs or adenoviral vectors expressing Gag and Env. This T cell independent secondary
antibody response to Env was reduced after stimulation with VLPs modified to contain monomeric membrane
bound gp130 surface subunit of Env and undetectable after injection of soluble gp130.
Conclusions: Membrane-bound trimeric Env seems to be responsible for the maintenance of high levels of anti-Env
antibodies during progression to AIDS. This T cell independent secondary antibody response may prevent T
cell-dependent affinity maturation and thus contribute to viral immune escape by favoring persistence of
non-protective antibodies.
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Although HIV infection induces a vigorous antibody re-
sponse to Gag and Env proteins, the induced antibodies
do not prevent progression to AIDS. The induction of
neutralizing antibodies seems to be too slow and ineffi-
cient to keep pace with the rapidly mutating HIV [1,2].
Whether other antibody-mediated antiviral effector
mechanisms, such as complement activation and anti-
body-dependent cytotoxicity, slow down the progression
of the disease is unknown [3-5]. The major targets for
antibody-mediated inhibition of HIV are the gp120* Correspondence: klaus.ueberla@ruhr-uni-bochum.de
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reproduction in any medium, provided the orsurface protein (SU), the gp41 transmembrane protein
(TM), and possibly the gp160 Env precursor protein.
However, the magnitude of the antibody response to Env
does not correlate with the slower progression of disease
[6-8]. While high levels of Env antibodies are maintained
throughout infection, the decline of Gag antibodies with
progressing HIV infection is an indicator for a poor
prognosis [6-11]. This correlation is unlikely to reflect a
direct antiviral activity of Gag antibodies, since Gag pro-
teins are either located inside an infected cell or inside
the virus particle with a lipid membrane blocking the ac-
cessibility of Gag proteins by antibodies. Macaques
chronically infected with simian immunodeficiency virus
also maintained high levels of anti-Env antibodies,
whereas anti-Gag antibodies declined with progression
to AIDS [12,13]. It was, therefore, suggested that thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and






































Figure 1 Western blot analyses. 293 T cells were co-transfected
with Sgpsyn and the indicated Env expression plasmids. Supernatants
of transfected cells (left) and VLPs partially purified and concentrated
by ultracentrifugation (right) were analysed by Western blot for SIV
proteins.
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due to the loss of CD4+ T cell help, while a T cell inde-
pendent antibody response to Env allows persistence of
Env antibodies [6]. A differential regulation of Gag and
Env antibody responses was also observed during natural
non-progressive infection of African green monkeys.
While anti-Gag antibody responses were weak or not
observed at all, the anti-Env antibody responses were as
robust as observed in HIV infection [14]. Since the limi-
tation of immune activation has been proposed to be a
key determinant of non-pathogenic immunodeficiency
virus infections [15], the paucity of the Gag-specific anti-
bodies might be due to a limited T helper cell activation.
A T cell-independent Env antibody response might then
explain the high levels of Env antibodies observed.
The molecular mechanisms mediating the differential
requirement of Gag and Env antibodies for T cell help
have not been unraveled. Presentation of trimeric Env in
a repetitive manner on the surface of virus particles or
infected cells might allow cross-linking of Env-specific B
cell receptors providing the first signal during B cell acti-
vation. However, a T cell independent antiviral antibody
response seems to depend on the precise arrangement of
the viral surface protein on the viral particle. Infection
with vesicular stomatitis virus, which forms viral parti-
cles with densely packed G protein spikes, induces T cell
independent antibody responses. In contrast, antibody
responses to infection with lymphocytic choriomeningi-
tis virus, the virions of which contain less densely
packed spikes, are T cell dependent [16]. In addition to
the particulate nature of the HIV virion, gp120 was
found to have direct B cell stimulatory activity [17].
Thus, gp120 SU might provide both cross-linking of sur-
face BCR (signal 1) and an innate stimulus (signal 2).
Theoretically, these two signals alone could be sufficient
to trigger differentiation of naïve Env-specific B cells
into Ig secreting plasma cells [18].
A T cell independent Env antibody response might also
play an important role in viral immune escape: the affinity
and avidity of T cell independent Env antibodies might
be too low for efficient neutralization. Thus, a better
understanding of the differential regulation of Gag and
Env-specific B cell responses might provide further
insights in the pathogenesis of HIV and guide novel strat-
egies in HIV vaccine development. In the present report,
we therefore provide a side by side comparison of Env and
Gag-specific primary and secondary antibody responses in
immunocompetent and T cell deficient mice.
Results
Production and characterization of immunogens
During virus infection, the immune system encounters
viral proteins either in the form of infected cells, viral
proteins released from infected cells, or viral particles.Since it is not known which of these forms of antigens
actually shape the B cell response to immunodeficiency
viruses, we wanted to mimic these different forms of viral
antigens in a mouse model. Since mice are not suscep-
tible to immunodeficiency virus replication, we reasoned
that injection of adenoviral vectors encoding Gag-Pol
and Env into mice should result in vector transduced
cells producing and releasing the viral proteins in a simi-
lar antigenic form as immunodeficiency virus infected
cells.
To make sure, that the murine immune systems also
encounters sufficient amounts of virions, virus-like parti-
cles were also prepared ex vivo and used as immunogens.
In comparison to natural immunodeficiency virus infec-
tions which leads to production of over 1010 viral particles
each day [19,20], the amount of Env and Gag of the VLPs
or the amount of Env and Gag produced after adenoviral
vector immunization is probably small. To be able to fur-
ther extend the planned mouse studies into a more rele-
vant animal model for the pathogenesis of AIDS, we used
two previously described adenoviral vectors encoding
Gag-Pol and Env of SIV [21]. The virus-like particles of
SIV were produced by transient co-transfection of 293 T
cells with codon-optimized gag-pol and env expression
plasmids. To enhance incorporation of SIV Env into the
VLPs, the expression plasmid gp140-GCD was constructed
in which the coding region of the intracytoplasmic do-
main of SIV is replaced by the G protein of vesicular sto-
matitis virus. Western blot analysis revealed that SIV Env
could be detected in VLPs concentrated from the super-
natant of gp140-GCD-transfected cells by ultracentrifuga-
tion through a 20% sucrose cushion, but not in the
unconcentrated supernatant of these cells (Figure 1). In
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pression plasmid encoding the secreted gp130 surface
subunit of SIV (gp130-His) contained detectable levels of
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Figure 2 Antibody response to VLP and adenoviral vector immunizat
Mice were immunized with SIV VLPs at the indicated dose of gp140 ectod
vector immunizations (Ad-SIV) with 1 × 109 particles were performed on da
Env and Gag were determined before immunization (0) and on day 49.Induction of humoral immune responses against Gag and
Env
To confirm that the VLPs and the adenoviral vectors
were immunogenic, immunocompetent mice were
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adenoviral vectors encoding Gag-Pol and Env (Figure 2).
After two injections of Ad-SIV, mice raised IgG1 and
IgG2a antibodies to Gag and Env. Three VLP immuniza-
tions induced similar levels of IgG1 and IgG2a antibodies
to Env. However, Gag antibody responses were 10- to
100-fold weaker in the VLP immunization group than in
the adenoviral vector group, which is consistent with
poor accessibility of Gag inside the virus particle.
T cell deficient nude mice were injected in parallel
with the same immunogens to explore potential differ-
ences in the T-cell independent antibody response to
Gag and Env. Immunization of nude mice with VLPs
(100 or 400 ng of Env) by either subcutaneous or intra-
venous injection did not raise Gag and Env specific anti-
body levels above the background levels seen in pre-
immune sera (Figure 2 A,B). The nude mice were immu-
nized with a wider dose range of VLPs to exclude the
possibility that passing a narrow threshold level may
turn a T cell dependent antibody response into a T cell
independent response as observed previously [22]. Sub-
cutaneous immunization with Ad-SIV did not induce
Gag- or Env-specific antibodies (Figure 2A,B) either.
Since the T cell deficient mice were not able to generate
IgG1 and IgG2a antibody responses, we also investigated


















































Figure 3 T cell independent secondary Env antibody responses after
subcutaneously with 1 × 109 particles of Ad-SIV or as a control Ad-GFP. Six
mice resulting in SIV B cell recipient and control B cell recipient mice. At 6,
cell recipient, and Ad-SIV immunized donor mice were boosted i.v. with VL
antibody levels to Env and Gag were determined at the indicated time po
animals per group are given. The shaded area indicates background antiboand Env-specific IgM antibodies were indeed induced at
low levels after intravenous injection of the VLPs and
after the adenoviral vector immunization (Figure 2C).
Thus, priming of Env- and Gag-specific IgG antibody
responses by VLPs and adenoviral vectors greatly depends
on T cells.
T cell independent secondary antibody responses against
Gag and Env
Persistence of antibodies to Env, but not Gag during
progression to AIDS in HIV-infected individuals or SIV-
infected macaques suggested a T cell independent Env-
specific antibody response, which was clearly not
observed during immunization of T cell deficient mice.
One major difference between the nude mouse model
and natural immunodeficiency virus infections is that, in
the latter, priming occurs in immunocompetent hosts.
To explore, whether secondary antibody responses to
Env are T cell independent, B cell responses were first
induced in immunocompetent mice by immunization
with adenoviral vectors expressing SIV Gag and Env
(Figure 3A). As a control for nonspecific immune activa-
tion by the adenoviral vector, a group of mice received
an adenoviral vector expressing GFP. Six weeks after
adenoviral vector immunization, splenic B cells were iso-
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41 days after the B cell transfer. After the second VLP
injection, nude mice that received Gag and Env-primed
B cells mounted substantial Env-specific IgG1 and IgG2a
antibody levels (Figure 3B). The Env specific antibody
response observed in the nude mice was not due to de
novo priming of B cells since transfer of B cells from
mice immunized with the adenoviral GFP vector did not
result in Env-specific antibody responses in the recipient
nude mice after VLP immunization. Gag-specific sec-
ondary antibody responses could not be detected after
VLP booster immunizations in the recipient nude mice
even after transfer of Gag-primed B cells (Figure 3C).
Since our VLP immunization induced only poor Gag-
specific antibody responses even in immunocompetent
mice, it remained unclear, whether the absence of Gag-
specific secondary antibody responses was due to their T
cell dependence or due to poor accessibility of Gag in-
side the viral particle. To overcome this limitation, nude
mice were also immunized with Ad-SIV after adoptive
transfer of primed B cells (Figure 4A,B).
Nude mice, that had received Gag and Env-primed B
cells developed Gag-specific antibodies only after
immunization with the adenoviral vector, but not after
VLP injection (Figure 3B). However, the Gag-specific anti-
body levels were just above background and substantially
lower than the Env-specific antibody levels (Figure 4A).
This experiment once more confirmed poor induction of
Gag-specific secondary antibody responses, while Env-
specific secondary immune responses are strongly induced
by both the Ad-SIV and VLP immunization indicating that
secondary antibody responses to Env are less dependent
on T cell help than Gag-specific secondary antibody
responses.Structural requirements for T cell independent secondary
antibody responses to env
The functional Env spikes of human and simian im-
munodeficiency viruses are formed by cleavage of a tri-
mer of the gp160 Env protein into three SU and three
transmembrane TM subunits, which stay non-covalently
linked. Expression of SU in the absence of TM leads to
secretion of monomeric SU proteins which can be puri-
fied from the supernatant of transfected cells (Figure 1).
To explore whether the monomeric SU is sufficient to
trigger T cell independent secondary Env responses, one
group of nude mice, which had received Gag and Env-
primed B cells, was also boosted with secreted gp130 SU
(Figure 4). Western blot analyses of supernatants of
transfected cells revealed the presence of gp130 SU in a
form that could not be pelleted through a 20% sucrose
cushion (Figure 1). The amount of secreted gp130 SU
used for the immunization of the B-cell recipient nudemice was adjusted to the total gp130 content of the VLP
preparations.
In contrast to the boost with VLPs or the adenoviral
vectors, secreted gp130 SU did not trigger secondary Env
antibody responses in T cell deficient mice (Figure 4B).
This suggests that the repetitive arrangement of Env on
the surface of VLPs or Env-expressing cells is required. Al-
ternatively, the trimeric structure of the envelope spike
could trigger B cell receptor cross-linking leading to T cell
independent secondary Env antibody responses. We
therefore generated VLPs containing a membrane
anchored form of bona fide monomeric gp130 SU. This
was achieved by fusion of the gp130 SU subunit to the
transmembrane domain of the G protein of vesicular sto-
matitis virus. Western blot analyses confirmed that this
membrane anchored form of gp130 was no longer
secreted at detectable levels into the supernatant of trans-
fected cells (Figure 1). In contrast to the secreted gp130, it
could be pelleted by ultracentrifugtion through a 20% su-
crose cushion (Figure 1) suggesting efficient incorporation
into VLPs.
Boosting nude mice that had received Gag- and Env-
primed B cells with gp130-VLPs triggered secondary
Env-specific IgG1 and IgG2a antibody responses that
were approximately 2 to 20-fold lower than those
obtained after a boost with VLPs containing the same
amount of the wild type ectodomain of Env (Figure 5).
This indicates that the level of T cell independent Env-
specific secondary antibody response depends on the re-
petitive arrangement of Env on the surface of infected
cells or on VLPs. In comparison to membrane-bound
monomeric form of gp130 SU, the trimeric nature or a
particular conformation of the native Env spike seems to
further increase T cell independent induction of the
secondary Env antibody responses.
Discussion
HIV-1 infection leads to an early and vigorous humoral
immune response. Antibodies to gp120 SU and gp4l TM
become detectable first, but are followed shortly by anti-
bodies to Gag [23]. Sequential serum samples from HIV-
infected patients show a decline of antibodies to Gag and
Tat coinciding with more rapid progression to AIDS [24-
26]. This decline of the anti-Gag antibody response dur-
ing disease progression has been proposed to reflect the
loss of T cell help [6,27]. The maintenance of high levels
of anti-Env antibodies despite declining anti-Gag anti-
body levels indicates a differential requirement for CD4+
T cell help. Similar observations were made in rhesus
monkeys experimentally infected with SIV [12,13]. Since
several spikes of the trimeric complexes are presented on
the surface of virions and thus provide repetitive anti-
genic determinants, Env indeed possesses some charac-
teristics of a T-cell independent antigen [28].
A Env antibodies
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Figure 4 T cell independent secondary Env antibody responses after adoptive B cell transfer and stimulation with soluble gp130.
BALB/c donor mice were immunized subcutaneously with 1 × 109 particles of Ad-SIV or as a control Ad-GFP. Six weeks later splenic B cells from
both groups were transferred to nude mice resulting in SIV B cell recipient and control B cell recipient mice. At 4, 13 and 25 days after B cell
transfer, SIV B cell recipient, control B cell recipient and Ad-SIV immunized donor mice were boosted i.v. with VLPs containing 300 ng of the
gp140 ectodomain or with 300 ng of secreted gp130 SU. B cell recipient mice were also immunized s.c with Ad-SIV (109 particles, immunization
of day 13 ommitted). IgG1 and IgG2a antibody levels to Env (A) and Gag (B) were determined at the indicated time points after B cell transfer.
The mean and standard deviation of four animals per group are given. The shaded area indicates background antibody levels.
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able to elicit anti-Env antibody responses in a T cell inde-
pendent manner. It was previously reported that
immunization of CD4KO mice with HIV-1 VLPs pro-
duced by a baculovirus expression system in insect cells
induced Env-specific antibodies in mice independently
from T-helper cells [29]. However, co-purification ofbaculoviruses with the VLPs is suspected to provide sub-
stantial adjuvant effects [30], which limits the conclu-
sions that can be drawn with respect to T cell-
independent antibody responses induced by the lentiviral
VLPs itself. In our hands the immunization of nude mice
with Ad-SIV or SIV-VLPs produced in a human cell line
did not raise Env- or Gag-specific IgG immune
Donor mice
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Figure 5 T cell independent secondary Env antibody responses after adoptive B cell transfer and stimulation with VLPs containing
monomeric gp130 SU. BALB/c donor mice were immunized subcutaneously with 1 × 109 particles of Ad-SIV. Six weeks later, splenic B cells were
transferred into nude mice resulting in SIV B cell recipient mice. At 4, 35 and 41 days after B cell transfer, SIV B cell recipient and Ad-SIV
immunized donor mice were boosted i.v. with VLPs containing 300 ng gp140 ectodomain. B cell recipient mice were also immunized s.c with
Ad-SIV (109 particles, immunization of day 35 omitted) or i.v. with VLPs containing 300 ng of membrane-anchored monomeric gp130 (gp130-VLPs).
IgG1 and IgG2a antibody levels to Env and Gag were determined at the indicated time points after B cell transfer. The mean and standard deviation of
four animals per group are given. The shaded area indicates background antibody levels.
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to be immunogenic in immunocompetent BALB/c mice
(Figure 2A,B). This indicates that the primary antibody
response to SIV Env is T cell dependent in mice. How-
ever, we cannot exclude that the lack of T cell independ-
ent primary Env antibody responses in mice is due to
species-specific differences in the innate interaction of
Env with B cells, which warrants further investigations.
The longitudinal analyses of immune responses during
HIV and SIV infection suggest that the anti-Env anti-
body response is maintained in a T cell independent
manner. This hypothesis could be confirmed by our
mouse experiments. After adoptive transfer of B cells
from SIV immunized immunocompetent mice into nude
mice, exposure of the recipient mice to VLPs or Ad-SIV
resulted in an Env-specific IgG antibody response,
whereas anti-Gag antibody responses were not elicited
(Figure 3, 4, 5). Since we observed the Env antibody
responses only in T cell deficient nude mice receiving
primed B cells, the detected antibody response must be
T cell independent. Neither the autologous B cells of
nude mice nor B cells transferred from Ad-GFP immu-
nized mice can raise an Env antibody response indicat-
ing that the primary antibody response is T cell
dependent.
In our transfer experiments, B cells were obtained
from the spleens of the primed BALB/c mice six weeks
after single Ad-SIV immunization. Since the transferred
B cells did not produce Env- or Gag-specific antibodiesin recipient nude mice without antigen re-stimulation
(Figure 3), they should be predominantly composed of
antigen-specific memory B cells [31-33]. Memory B cells
circulate as a backup system and provide polyclonal
maintenance. Upon re-exposure to the same antigen,
they differentiate into new plasma cells leading to a
rapid recall response [32,33].
In all the B cell transfer experiments in nude mice,
anti-Gag humoral immune responses were not observed
after antigen re-stimulation. However, we could demon-
strate T cell independent differentiation of Env-specific
memory B cells into IgG producing plasma cells probably
by the direct engagement of the BCR. Although antibody
production is believed to be dependent on delivery of a
second signal, in the absence of T cell help, the second
signal could be potentially provided by other signaling
pathways including those mediated via pattern recogni-
tion receptors [34]. The HIV envelope was shown to trig-
ger human B cells through a CD40-independent
mechanism involving innate BAFF and mannose C-type
lectin receptors [17]. Thus, simultaneous activation of
antibody-producing B cells via this innate mechanism
and the extensive cross-linking of BCRs by such multiva-
lent ligands as the Env spikes might itself be sufficient to
induce proliferation of B cells, as previously discussed
[35].
Our mouse model also allowed us to explore the struc-
tural requirements for the T-cell independent secondary
antibody responses to Env. Each of the Env spikes of
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three SU and TM subunits, which are non-covalently
linked and embedded in the cytoplasmic membrane of
infected cells and circulating virions. At the same time,
SU is constantly shedded in a monomeric form. There-
fore, we determined whether the secreted SU can also
trigger T-cell-independent secondary antibody responses.
The secreted monomeric gp130 SU clearly failed to trig-
ger secondary antibody responses, whereas the same
amounts of gp130 incorporated into VLPs within the
wild type multimeric Env spikes induced good secondary
IgG antibody responses to Env (Figure 4).
To answer the question whether the T-cell-independent
secondary antibody is elicited by the trimeric nature of
Env or is due to the repetitive nature of the Env-spikes,
we immunized B cell recipient nude mice with VLPs con-
taining membrane-bound monomeric form of Env. The
secondary antibody response to Env after stimulation with
VLPs containing monomeric membrane-bound SU was
detectable, but it was lower in magnitude than the anti-
body response after stimulation with VLPs containing tri-
meric forms of Env (Figure 5). The repetitive nature of the
membrane-anchored monomeric SU probably helps to
cross-link multiple B cell receptors resulting in the stimu-
lation of anti-Env antibody response. However, the higher
magnitude of antibody response after immunization with
VLP containing trimeric Env suggests that the Env trimers
are even more efficient in BCR cross-linking and/or pro-
viding the second signal.
Although there are numerous reports indicating that
the generation of plasma cells from virus-specific mem-
ory B cell is a strictly T cell-dependent immune reaction
[31,32,36], there is another publication demonstrating
that T-cell-independent humoral immune responses to
enveloped viruses can occur. Using adoptive transfer of
memory B cells from immunocompetent mice immu-
nized with human cytomegalovirus into RAG-1−/− ani-
mals, Hebeis and colleagues observed T cell independent
activation of memory B cells specific for viral surface
proteins after challenge of the B-cell recipient mice with
the same virus [37]. As suggested by the authors, this T
cell independent antiviral memory B cell activation
could be particularly beneficial during reactivation of
viruses in immunosuppressed patients [37,38]. However,
the proposed T cell independent activation mechanism
could be a serious disadvantage for the host during in-
fection with viruses with high mutation rates. After in-
fection of a host, HIV continues to accumulate
mutations in B cell epitopes targeted by neutralizing
antibodies. Sera from HIV-infected patients were unable
to neutralize HIV isolated from the same donor at the
time of serum sampling, but could readily neutralize iso-
lates obtained at previous sampling time points [39,40].
Since there seems to be a competition between newlygenerated plasmablasts and established resident long-
lived plasma cells for habitation of a limited number of
survival niches [33], the B cell responses to past variants
of Env might therefore interfere with timely generation
of neutralizing antibodies targeting the escape mutants.
T cell independent Env antibody production might
therefore contribute to the immune escape of immuno-
deficiency viruses from antibody mediated immune
mechanisms.Conclusions
Our findings are consistent with the hypothesis that im-
pairment of T cell help during progression to AIDS leads
to decline in effective plasma cells generation from Gag-
specific memory B cells established during the initial
phase of HIV infection. Therefore, the anti-p24 antibody
response decays with time in the advanced stages of the
disease [6,41]. Our findings further suggest that trimeric
membrane-associated forms of Env are able to continuously
stimulate generation of Env-specific plasma cells even upon
total loss of cognate help.Methods
Plasmids and recombinant adenoviruses
The codon-optimized SIV-gag-pol expression plasmid
Sgpsyn has been previously described [42]. Codon-
optimized fragments (obtained from Geneart, Regens-
burg, Germany) encoding amino acids 23 to 682
(gp140 ectodomain and TM domain) or 23 to 521
(gp130 SU) of SIVmac239 env (according to GenBank
entry M33262.1) were cloned into pcDNA3.1+ (Invi-
trogen) downstream of the coding region for the
leader peptide of tissue plasminogen activator (amino
acid 1 to 23 of GenBank: AAA61213.1). A codon-
optimized fragment encoding the cytoplasmic domain
of the G-protein of VSV (amino acid 97 to 122 of
GenBank: CAA24524.1 and derived from plasmid
pCD-Gsynmut [43]) was fused in frame to the gp140
ectodomain construct to generate plasmid gp140-GCD.
A codon-optimized fragment encoding the transmem-
brane and cytoplasmic domains of the G-protein of VSV
(amino acid 52 to 122 of GenBank: CAA24524.1) was
fused in frame to the gp130 construct to generate plasmid
gp130-GTM. Fusing the coding region for the 6xHis-tag to
the gp130 SU construct resulted in plasmid gp130-His. A
codon-optimized fragment spanning SIV p27CA (Gag
amino acid 135 to 363 of Genbank entry M33262.1) was
also fused in frame with a coding region for a 6xHis-tag
and cloned into pET15b vector (Novagen) to generate the
SIVp27pET15b plasmid.
The construction and production of the adenoviral vec-
tors expressing codon-optimized SIV gag-pol (Ad-Sgpsyn),
codon-optimized SIV env (Ad-Senv-co), and GFP (Ad-
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to a one-to-one mixture of Ad-Sgpsyn and Ad-Senv-co.
VLP production and characterisation
HEK 293 T cells were cultured in DMEM (Invitrogen,
Karlsruhe, Germany) supplemented with penicillin,
streptomycin and 10% FCS. Virus like particles contain-
ing the wild type ectodomain (VLP) or the membrane-
bound surface subunit of Env (gp130VLP) were pro-
duced in 293 T cells by transient cotransfection of 293 T
cells with Sgpsyn and gp140-GCD or gp130-GTM respect-
ively. Eight hours after transfection, the FCS-containing
DMEM was replaced by serum-free AIM-V medium
(Invitrogen). The conditioned medium was harvested
24 h later and the VLPs were concentrated by ultracen-
trifugation through 20% sucrose in Optima L-70 K,
Beckman ultracentrifuge at 25000 rpm for 2 h using a
SW28 rotor as described previously [45]. The pellet was
resuspended in approximately 200 μl PBS per 30 ml
supernatant of transfected cells and stored at −80°C for
subsequent experiments. Secreted SIV gp130 was puri-
fied from the supernatant of gp130-His-transfected
293 T cells using the ProPur Midi MC kit (Nunc,
Germany).
The Env and Gag content of the immunogens was
determined by coating ELISA plates with the SIV gp130
SU preparation or with VLP preparations lysed in 0.2%
Triton X-100. Env was then detected by the KK45
monoclonal antibody directed against SIVmac251 gp120
(NIH AIDS research and reference reagent program)
and Gag proteins by an HIV-1 p24 specific monoclonal
antibody, purified from the hybridoma 183-H12-5 C
(NIH AIDS research and reference reagent program).
Binding of these antibodies was detected by a peroxidase-
labelled secondary antibody. Defined amounts of recom-
binant SIV gp130 SU (EVA670, NIBSC) and SIV p27CA
(EVA643) were coated and analysed in parallel to obtain
standard curves. The endotoxin levels of the immunogens
were determined by the Limulus assay kit (QCL-1000W
Chromogenic LAL Endpoint Assay, Cambrex) and it was
made sure that the final endotoxin levels remained below
0.1 units per injection dose.
Animal experiments
Immunodeficient female nude mice (BCAnN.Cg-
Fox1nu/Crl) and immunocompetent female BALB/c
mice, 5 to 7 weeks old, were purchased from Charles
River Laboratories and housed in the central animal
facility of the Medical Faculty of the Ruhr-University.
Animal care and use were in compliance with the Ger-
man Animal Protection Law. Approval for the animal
experiments was obtained from the Landesamt für
Natur, Umwelt und Verbraucherschutz Nordrhein-
Westfalen (reference number 50.8735.1. Nr. 111/2).For subcutaneous injections, 50 μl of each immunogen
were injected into both hind foot pads, a total volume
of 300 μl was injected for intravenous administration
of VLPs in the lateral tail vein after warming the mice
with infrared heating lamp for 40 to 60 seconds. Blood
samples were obtained by puncture of the retro-orbital
plexus under isoflurane inhalation anaesthesia of the
mice.
For the B-cell transfer experiments, BALB/c mice were
immunized with Ad-SIV or Ad-GFP (1x109 particles, s.c).
On week 6 after the immunization, the B cells were iso-
lated from spleens by the B cell isolation kit (Miltenyi Bio-
tec GmbH). The purity of isolated cells reached 96–98%
as confirmed by flow cytometry. B cells were pooled and
the approximate number of B cells purified per mouse
was injected intravenously into each recipient nude
mouse. Each recipient group had four mice.
Measurement of serum Ab level (ELISA)
The Gag antigen (p27CA) for the ELISA was produced
in BL21(DE3) cells transformed by SIVp27pET15b as
suggested by the manufacturer (Stratagene). The protein
was purified from the periplasm by its His-tag using the
ProPur Midi MC kit (Nunc, Denmark) according to
the manufacturer’s instructions. The protein prepara-
tions were 90–95% pure as judged by Coomassie stain-
ing. To determine serum antibody levels to Env or Gag
flat-bottom 96-well plates (Nunc) were coated overnight
with 200 ng p27CA or secreted SIVgp130 produced in
293 T cells prior to blocking with 5% fat-free milk. After
washing, the wells were incubated with dilutions of the
sera from immunized mice and bound IgG1 and IgG2a
antibodies were detected using HRP-conjugated secondary
antibodies obtained from Sigma Aldrich. After adding the
enhanced chemiluminescent substrate the relative light
units emitted were determined in a microplate lumin-
ometer. Serum dilutions within the dynamic range of the
ELISA were used.
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